share_log

石藥集團：石藥創新製藥股份有限公司截至2024年9月30日止9個月之未經審計財務資料

CSPC PHARMA: UNAUDITED FINANCIAL INFORMATION OF CSPC INNOVATION PHARMACEUTICAL CO., LTD. FOR THE NINE MONTHS ENDED 30 SEPTEMBER 2024

HKEX ·  Oct 23 06:14

Summary by Moomoo AI

石藥集團旗下附屬公司石藥創新製藥股份有限公司（簡稱「石藥創新」，股票代碼：300765）於2024年10月23日發佈了截至2024年9月30日止9個月的未經審計第三季度報告。該報告顯示，石藥創新在報告期內的營業收入較上年同期下降了14.48%，而歸屬於上市公司股東的淨利潤更是大幅下滑了98.03%。此外，基本每股收益和稀釋每股收益均下降了超過97%。石藥創新的財務狀況顯示，其貨幣資金、應收款項融資、以及應付帳款等項目均出現了顯著變動，其中貨幣資金減少了65.69%，主要原因是公司購買大額定期存單、進行股份回購、現金分紅以及支付研發款項等。石藥集團強調，該財務報告僅反映石藥創新的財務狀況，並非石藥集團整體的財務資料，提醒投資者在買賣本公司證券時應審慎行事。
石藥集團旗下附屬公司石藥創新製藥股份有限公司（簡稱「石藥創新」，股票代碼：300765）於2024年10月23日發佈了截至2024年9月30日止9個月的未經審計第三季度報告。該報告顯示，石藥創新在報告期內的營業收入較上年同期下降了14.48%，而歸屬於上市公司股東的淨利潤更是大幅下滑了98.03%。此外，基本每股收益和稀釋每股收益均下降了超過97%。石藥創新的財務狀況顯示，其貨幣資金、應收款項融資、以及應付帳款等項目均出現了顯著變動，其中貨幣資金減少了65.69%，主要原因是公司購買大額定期存單、進行股份回購、現金分紅以及支付研發款項等。石藥集團強調，該財務報告僅反映石藥創新的財務狀況，並非石藥集團整體的財務資料，提醒投資者在買賣本公司證券時應審慎行事。
cspc pharma's subsidiary cspc innovation pharmaceuticals co., Ltd. (referred to as "cspc innovation", stock code: 300765) released the unaudited third quarter report for the nine months ended on September 30, 2024 on October 23, 2024. The report shows that cspc innovation's revenue during the reporting period decreased by 14.48% compared to the same period last year, while the net profit attributable to shareholders of the listed company plummeted by 98.03%. In addition, both basic earnings per share and diluted earnings per share decreased by over 97%. The financial situation of cspc innovation indicates significant changes in items such as monetary funds, accounts receivable financing, and accounts payable, with a 65.69% decrease in monetary funds, mainly due to the company's purchase of large-term deposits, share repurchases, cash dividends, and payments for research and development expenses. cspc pharma emphasizes that this financial report only reflects the financial situation of cspc innovation, not the overall financial data of cspc pharma, reminding investors to exercise caution when trading the company's securities.
cspc pharma's subsidiary cspc innovation pharmaceuticals co., Ltd. (referred to as "cspc innovation", stock code: 300765) released the unaudited third quarter report for the nine months ended on September 30, 2024 on October 23, 2024. The report shows that cspc innovation's revenue during the reporting period decreased by 14.48% compared to the same period last year, while the net profit attributable to shareholders of the listed company plummeted by 98.03%. In addition, both basic earnings per share and diluted earnings per share decreased by over 97%. The financial situation of cspc innovation indicates significant changes in items such as monetary funds, accounts receivable financing, and accounts payable, with a 65.69% decrease in monetary funds, mainly due to the company's purchase of large-term deposits, share repurchases, cash dividends, and payments for research and development expenses. cspc pharma emphasizes that this financial report only reflects the financial situation of cspc innovation, not the overall financial data of cspc pharma, reminding investors to exercise caution when trading the company's securities.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1     View Translation

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Heat List
    US
    SymbolLatest Price% Chg

    No Data

    Hot News
    Updated